Next Day DeliveryRegistered Pharmacy100% OnlineFully Inspected & Regulated ServicesApproved UK-licensed TreatmentsNext Day DeliveryRegistered Pharmacy100% OnlineFully Inspected & Regulated ServicesApproved UK-licensed Treatments
31 May 2026
8min read
Contents
Author
Finasteride is the most effective oral treatment for male pattern hair loss in the UK. It is also the treatment most surrounded by anxiety, online speculation and second-hand horror stories.
The honest picture is that most men tolerate it well, the side effects are real but uncommon, and an informed decision is much easier than a frightened one. This guide is the LYV Clinical Team's straightforward summary of what the evidence actually says.
If you are comparing finasteride side effects, finasteride for hair loss, finasteride 1 mg side effects, or hair loss treatment UK men, the most useful approach is to separate common, uncommon, rare and contested risks clearly.
You can also read LYV’s related guides on male pattern hair loss in the UK, hair loss causes and treatment myths, and proven hair growth options in 2026.
The most discussed finasteride side effects are sexual side effects, including reduced libido, erectile dysfunction and reduced ejaculate volume. These are uncommon, but they should be explained honestly before a man starts treatment.
In the original registration trials, around 1.8% of men taking finasteride reported sexual side effects compared with 1.1% taking placebo. That means the number of men with a side effect attributable specifically to the medication was roughly 1 in 100.
Most side effects, when they occur, improve after stopping finasteride. Mood changes and persistent symptoms are less common but important enough to be included in the consultation and informed-consent conversation.
Finasteride 1 mg blocks the enzyme 5-alpha reductase, which converts testosterone into dihydrotestosterone (DHT). DHT is the hormone that drives the follicle miniaturisation underlying male pattern hair loss.
Reducing scalp DHT by around 60% slows or stops the progression of hair loss in around 90% of men, with regrowth in around 60–70% over 12 months. The benefit is real and well-documented across multiple large UK and international trials.
This is why finasteride remains one of the most important evidence-based options for men with androgenetic alopecia. It does not simply make hair look thicker temporarily; it targets the hormonal driver responsible for progressive follicle miniaturisation.
The headline concern is sexual side effects: reduced libido, erectile dysfunction, and in rarer cases reduced ejaculate volume. In the original Merck registration trials, around 1.8% of men on finasteride reported these effects compared with 1.1% on placebo — meaning roughly 1 in 100 men had a side effect attributable specifically to the drug.
UK post-marketing data has been broadly consistent. Most of these effects resolve on stopping the medication, usually within weeks.
Two important nuances are worth flagging honestly. First, there is a contested condition called post-finasteride syndrome, or PFS, reported in a small number of men, in which sexual or mood symptoms are described as persisting after stopping the drug.
The MHRA, the European Medicines Agency and the British Association of Dermatologists have all reviewed this and the evidence base for PFS as a defined entity remains contested. Case reports exist, but causality and prevalence are unclear. The honest position is that it is rare if it exists at all, but it is part of the informed-consent conversation.
Second, mood symptoms — depression, anxiety, occasional reports of suicidal thinking — have been reported and are now in the patient information leaflet as a precaution. The absolute frequency is low. Any new mood change after starting finasteride should prompt stopping the medication and a clinical review.
Many men searching for finasteride side effects are specifically worried about sexual function. That is understandable. Hair loss treatment is elective, and men should feel clear about the balance between the expected benefit and the possible risk.
For most men, finasteride does not cause sexual side effects. For a small minority, symptoms may appear within the first few weeks or months. If symptoms begin after starting treatment, stopping for a supervised period can help clarify whether the medication is likely to be involved.
Two milder effects are worth knowing about: a transient initial shedding around 4–8 weeks after starting, and gynaecomastia, which is breast tissue tenderness or enlargement in a small proportion of men.
Initial shedding can look alarming, but it is usually a sign that the existing hair cycle is resetting. It commonly resolves over 2–3 months. The key is not to panic and stop treatment too early unless there are other concerning symptoms.
Gynaecomastia is uncommon and warrants stopping finasteride and arranging clinical review if it occurs.
Finasteride is also licensed at 5 mg for benign prostatic hyperplasia, or BPH — five times the hair-loss dose. Some of the side-effect concerns that circulate online refer to the 5 mg BPH dose or to the more potent dutasteride; they do not translate directly to the 1 mg hair-loss dose.
Effects on PSA testing, the prostate cancer screening blood test, occur with the 5 mg dose more than the 1 mg dose, but you should still mention any finasteride use to a doctor ordering a PSA test.
This is one reason why context matters. A side-effect discussion should be specific to finasteride 1 mg for male pattern hair loss, not a general internet discussion about every 5-alpha reductase inhibitor at every dose.
Finasteride is used differently depending on the condition being treated. The hair-loss dose is typically 1 mg, while the dose for enlarged prostate treatment is typically 5 mg. Online discussions sometimes mix these together, which can make the risk picture feel more confusing than it needs to be.
Finasteride is contraindicated in women, particularly women who are or could become pregnant, because the drug is teratogenic and can cause genital abnormalities in male foetuses. It is also contraindicated in patients with severe liver disease and patients with hypersensitivity to the drug.
Caution is needed in patients with a history of depression. Finasteride is not appropriate in adolescents because the long-term effects of suppressing DHT during continued development are not adequately studied.
The LYV hair-loss consultation explicitly covers the side-effect profile, the contested PFS conversation, mood-history screening, and the contraindication list. We do not recommend finasteride to patients where the risk-benefit picture is not favourable.
If you start finasteride and develop side effects, stop the medication and message the LYV Clinical Team. We will review and either advise on restarting at a lower frequency, switching to topical-only therapy, or stopping. There is no clinical pressure to continue treatment that is not suiting you.
If you are comparing treatment options, you may also find LYV’s pricing page, online pharmacy safety guide, and FAQs helpful before starting.
The reasonable approach for most men is to read the side-effect profile honestly, weigh the roughly 1–2% chance of sexual side effects against the roughly 90% chance of stabilising hair loss, recognise that side effects usually resolve on stopping, and recognise that the alternative — no treatment — means progressive hair loss for most men.
If you would prefer not to take an oral hormone-affecting medication, topical-only minoxidil therapy is a legitimate alternative. It is less effective for many men but has a much narrower side-effect profile.
Some patients prefer a topical finasteride formulation, where the drug is delivered to the scalp rather than systemically. Evidence for topical finasteride is emerging but smaller than for the oral formulation; LYV will discuss this option in the consultation if relevant.
Finasteride and minoxidil are often compared because they are the two most recognised evidence-based treatments for male pattern hair loss. They are very different medicines, and their side-effect profiles are also different.
Finasteride is oral and affects the DHT pathway. Minoxidil is topical and mainly acts locally on the scalp. For men who are nervous about oral medication, minoxidil may feel like a gentler starting point, but it may not address the hormonal driver of male pattern hair loss in the same way.
Start the LYV hair-loss assessment. The consultation covers the side-effect profile honestly, and the prescriber will recommend the right approach for your situation.
If finasteride is suitable, LYV can support treatment with plain packaging, clinician-led review, and clear advice on what to do if side effects occur.
This article is general information for UK adults and is not a substitute for personalised medical advice. Prescription-only medicines mentioned are dispensed only after a clinician-led online consultation through LYV Pharmacy (GPhC registration 9012803). If you have concerns about your symptoms or any medication you are taking, speak to your GP or call NHS 111.
